Palisade Bio Stockholder Meeting Update
Carlsbad, CA – Palisade Bio, Inc. (NASDAQ: PALI), recognized for its pioneering work in biopharmaceuticals aimed at treating autoimmune, inflammatory, and fibrotic diseases, has recently announced the adjournment of its special stockholders meeting due to insufficient attendees.
Understanding the Adjournment
The special meeting was convened, but with fewer than one-third of the outstanding shares present, it could not proceed with any business. This requirement ensures that decisions made represent a substantial portion of the company’s stakeholders. To allow for broader participation, the meeting has been adjourned and will reconvene at a later date.
New Meeting Details
The reconvened special meeting is set to take place virtually, providing greater accessibility for stockholders. Virtual formats allow for easier participation from those unable to attend in person, ensuring that all voices can be heard. This arrangement demonstrates Palisade's commitment to engaging with its shareholders effectively.
Efforts to Solicit Votes
Following the adjournment, Palisade Bio is actively reaching out to stockholders to encourage voting on the proposals detailed in their proxy statement. To secure sufficient votes for quorum, the company has partnered with Mediant Communications Inc., a proxy solicitation firm, highlighting their determination to facilitate stockholder involvement and decision-making.
Who Can Vote?
Voting is reserved for stockholders of record as of July 28, 2025. Those who participated by submitting proxies should know that their submissions will still count in the adjourned meeting unless they choose to revoke them. Furthermore, stockholders who have yet to cast their votes are urged to do so by the deadline of October 9, 2025.
Engaging Stockholders
Palisade Bio encourages all eligible stockholders to make their voices heard. For those needing assistance or lacking necessary voting materials, the company has made Mediant Communications Inc. available for support. This outreach exemplifies Palisade’s commitment to transparency and encouraging active participation.
Company’s Mission
As a clinical-stage biopharmaceutical organization, Palisade Bio is dedicated to innovating treatment options for patients facing challenging health conditions. Their targeted approach aims to advance their unique therapeutics, fundamentally changing how autoimmune and inflammatory diseases are treated. The company invites anyone interested in their mission to learn more through their official website.
Investor Relations Contact
If stockholders or potential investors have inquiries, they can reach out directly to the JTC Team, LLC—specifically, Jenene Thomas at 908-824-0775 or via email at PALI@jtcir.com.
Frequently Asked Questions
What was the reason for the adjournment of the stockholder meeting?
The meeting was adjourned due to a lack of quorum, meaning fewer than one-third of the outstanding shares were present.
When will the adjourned stockholder meeting reconvene?
The reconvened meeting is scheduled for October 10, 2025, at 10:00 a.m. Pacific Time.
How can stockholders who haven't voted participate?
Stockholders of record as of July 28, 2025, can vote until October 9, 2025, at 11:59 p.m. Pacific Time.
Who can vote at the special meeting?
Only stockholders of record on the specified record date are eligible to vote at the meeting.
How can stockholders get help with voting?
If assistance is required, stockholders can contact Mediant Communications Inc. for help with their proxy or voting forms.
